Several compounds were targeting the PI3K/AKT pathway, such as rigosertib, MK-2206, AZD6482, TGX-221, NVP-BEZ235, and targeting the JAK/STAT pathway, like ruxolitinib and AZD1480, which were significantly correlated to STAT3 expression in cancer cell lines. The gene discussed is STAT3; the disease is cancer.